Ayşe Enise Göker1, Enis Ekincioglu2, Maide Hacer Alagöz3, Ruslan Hummatov1, Melis E Arkan1, Ayca Baskadem Yilmazer1, Arzu Güngör Doğuşlu1, Yavuz Uyar1. 1. Department of Otorhinolaryngology-Head and Neck Surgery, Okmeydani Training and Research Hospital, University of Health Science, Istanbul, Turkey. 2. Department of Otorhinolaryngology-Head and Neck Surgery, Okmeydani Training and Research Hospital, University of Health Science, Istanbul, Turkey. dr.enisekincioglu@gmail.com. 3. Department of Biochemistry, Okmeydani Training and Research Hospital, University of Health Science, Istanbul, Turkey.
Abstract
OBJECTIVE: To investigate the association of allergic rhinitis (AR) severity with neutrophil-lymphocyte and platelet-lymphocyte ratios in adult patients. METHODS: The study design was prospective observational study and the study included 209 AR patients and 243 healthy individuals. The patient group comprised 38.2% males with a mean age of 31.8 years. All patients who were diagnosed with persistent AR were included. The healthy control group comprised 52.7% males with a mean age of 32.3 years. The blood examination results of patients and healthy individuals were compared in terms of neutrophil-lymphocyte and platelet-lymphocyte ratios. The values were further compared within the patient group, according to AR severity. RESULTS: The neutrophil-lymphocyte ratio was 1.70 ± 0.65 in the healthy group and 2.02 ± 1.24 in the patient group. The platelet-lymphocyte ratio result was 100.85 ± 25.33 in the healthy group and 120.67 ± 40.59 in the patient group. When we compared the neutrophil-lymphocyte and platelet-lymphocyte ratios between the groups, we found statistically significant differences in both ratios (p = 0.003, p = 0.000, respectively). Both the neutrophil-lymphocyte and the platelet-lymphocyte ratios were higher in patients with moderate-severe AR. CONCLUSION: Both neutrophil-lymphocyte and platelet-lymphocyte ratios are useful markers for diagnosis of persistent AR. Specialists may benefit from these markers to assess the severity of the disease at the beginning of the diagnostic process.
OBJECTIVE: To investigate the association of allergic rhinitis (AR) severity with neutrophil-lymphocyte and platelet-lymphocyte ratios in adult patients. METHODS: The study design was prospective observational study and the study included 209 ARpatients and 243 healthy individuals. The patient group comprised 38.2% males with a mean age of 31.8 years. All patients who were diagnosed with persistent AR were included. The healthy control group comprised 52.7% males with a mean age of 32.3 years. The blood examination results of patients and healthy individuals were compared in terms of neutrophil-lymphocyte and platelet-lymphocyte ratios. The values were further compared within the patient group, according to AR severity. RESULTS: The neutrophil-lymphocyte ratio was 1.70 ± 0.65 in the healthy group and 2.02 ± 1.24 in the patient group. The platelet-lymphocyte ratio result was 100.85 ± 25.33 in the healthy group and 120.67 ± 40.59 in the patient group. When we compared the neutrophil-lymphocyte and platelet-lymphocyte ratios between the groups, we found statistically significant differences in both ratios (p = 0.003, p = 0.000, respectively). Both the neutrophil-lymphocyte and the platelet-lymphocyte ratios were higher in patients with moderate-severe AR. CONCLUSION: Both neutrophil-lymphocyte and platelet-lymphocyte ratios are useful markers for diagnosis of persistent AR. Specialists may benefit from these markers to assess the severity of the disease at the beginning of the diagnostic process.
Entities:
Keywords:
Allergic rhinitis; Neutrophil–lymphocyte ratio; Platelet–lymphocyte ratio
Authors: J Bousquet; N Khaltaev; A A Cruz; J Denburg; W J Fokkens; A Togias; T Zuberbier; C E Baena-Cagnani; G W Canonica; C van Weel; I Agache; N Aït-Khaled; C Bachert; M S Blaiss; S Bonini; L-P Boulet; P-J Bousquet; P Camargos; K-H Carlsen; Y Chen; A Custovic; R Dahl; P Demoly; H Douagui; S R Durham; R Gerth van Wijk; O Kalayci; M A Kaliner; Y-Y Kim; M L Kowalski; P Kuna; L T T Le; C Lemiere; J Li; R F Lockey; S Mavale-Manuel; E O Meltzer; Y Mohammad; J Mullol; R Naclerio; R E O'Hehir; K Ohta; S Ouedraogo; S Palkonen; N Papadopoulos; G Passalacqua; R Pawankar; T A Popov; K F Rabe; J Rosado-Pinto; G K Scadding; F E R Simons; E Toskala; E Valovirta; P van Cauwenberge; D-Y Wang; M Wickman; B P Yawn; A Yorgancioglu; O M Yusuf; H Zar; I Annesi-Maesano; E D Bateman; A Ben Kheder; D A Boakye; J Bouchard; P Burney; W W Busse; M Chan-Yeung; N H Chavannes; A Chuchalin; W K Dolen; R Emuzyte; L Grouse; M Humbert; C Jackson; S L Johnston; P K Keith; J P Kemp; J-M Klossek; D Larenas-Linnemann; B Lipworth; J-L Malo; G D Marshall; C Naspitz; K Nekam; B Niggemann; E Nizankowska-Mogilnicka; Y Okamoto; M P Orru; P Potter; D Price; S W Stoloff; O Vandenplas; G Viegi; D Williams Journal: Allergy Date: 2008-04 Impact factor: 13.146
Authors: Arnoud J Templeton; Mairéad G McNamara; Boštjan Šeruga; Francisco E Vera-Badillo; Priya Aneja; Alberto Ocaña; Raya Leibowitz-Amit; Guru Sonpavde; Jennifer J Knox; Ben Tran; Ian F Tannock; Eitan Amir Journal: J Natl Cancer Inst Date: 2014-05-29 Impact factor: 13.506